Kornimate/medical-research-clean huggingface dataset:
effects of eccentric training on glycemic control and quality of life in patients with type ii diabetes mellitus

Conditions: Type II Diabetes Mellitus

Summary: diabetes is defined by the level of hyperglycemia its a metabolic chronic disorder that furthur lead to life threatning medical conditions however, the prevalence of diabetes is rapidly increasing day by day in both developed and developing countries making it global pandemic and type ii is more prevalent. life dependency is increased due to long term effects of diabetes in specifically older individuals. physical activity and exercise improves glucose tolerance and also reduces other life threatening diabetic complications, improving the quality of life in diabetic population.

diabetes is a metabolic chronic disorder and its becoming a global pandemic and its prevalence rises quickly in both developed and developing countries.diabetes confirmation is done through levels of hyperglycemia. according to american diabetic association level of hba1c is greater than 6.4 % indicate presence of diabetes.type ii is more prevalent and its deteriorting effect on body with increasing age are more pronounced.insuline resistance and impaired glucose tolerance are seen in type ii diabetes mellitus patients. studies depict that regular exercise improve glycemic control and improve insuline sensitivity and enhance glucose uptake by muscles. strength training enhance quality of life and protect your joints from injury. previous studies have specified the impact of several types of training on older adults, young healthy adults and diabetic patients but there is limited literature found in terms of solely observing the effect of eccentric training on glycemic control and quality of life in diabetic patient. current study was designed to determine the effects of eccentric training on glycemic control and quality of life in type ii diabetes mellitus.

Eligibility criteria:
inclusion criteria: * both gender * blood pressure should be \<140/90mm of hg * diagnosed diabetic patient (hba1c\>6.4%) * adults (age 40 +) from rawalpindi and islamabad exclusion criteria: * acute infection * history of recent trauma * acute coronary syndrome * peripheral vascular diseases

Keywords: eccentric training, diabetes mellitus
bipolar vs monopolar transurethral resection of the prostate (turp)

Conditions: BPH; Benign Prostatic Hyperplasia

Summary: this study will prospectively evaluate a new electrosurgical procedure (bipolar transurethral prostatectomy) in men with symptomatic benign prostatic hyperplasia.

the purpose of this study is to demonstrate that the bipolar turp using the vista controlled tissue resection system is safe and efficacious as a surgical treatment for men with symptomatic bph, allowing a reduction in the post-operative hospitalization. it is expected that bipolar turp will be safe and efficacious for the surgical treatment of bph and will allow a \ 50% of patients undergoing this procedure.

Eligibility criteria:
inclusion criteria: * symptomatic benign prostatic hyperplasia including patients with acute urinary retention; * peak urinary flow rate \< 12 ml/sec; * american urological association (aua) symptom score \> 12. exclusion criteria: * previous open or transurethral prostatic surgery; * history of urethral stricture; * failure to discontinue alpha-adrenergic blocking agents for at least 14 days prior to surgery; * failure to discontinue 5-alpha reductase inhibitor for at least 1 month prior to surgery; * patient interested in future fertility; * patient with known neurogenic bladder dysfunction; * untreated urinary tract infection; * american society of anesthesiologist (asa) class \>iii; * patients requiring anticoagulation with coumadin or heparin; * patient unable or unwilling to comply with follow-up schedule.

Keywords: transurethral resection of prostate turp
exoskeleton and spinal cord injury

Conditions: Spinal Cord Injuries

Summary: the purpose of the current study is to investigate the effects of powered exoskeleton (ekso) on cardiovascular performance as measured by resting blood pressure and heart rate, peak oxygen consumption during walking, energy expenditure, whole and regional body composition assessments. the effects of exoskeleton training on walking kinematics including stand-up time, walking time, distance covered and speed of walking will also be evaluated.

powered exoskeletons using robotic suits have recently been introduced for the rehabilitation of persons with spinal cord injury (sci). exoskeletons offer a unique opportunity for persons with sci to experience standing and walking at a low metabolic cost. evidence suggested that exoskeleton assisted walking can decrease spasticity and improve bowel movement. training may also improve the level of physical activity as well as psychological parameters that are likely to interfere with rehabilitation outcomes. previous studies reported that a frequency of 2-3 times per week or more for 1-2 hours may be beneficial in the rehabilitation of persons with sci. using exoskeletal-assisted walking to improve the level of physical activity may be appealing to persons with sci. exoskeleton training for 12 weeks may enhance energy expenditure, parameters of physical activity and result only on modest effects on both cardiovascular and body composition parameters. in other words, persons with tetraplegia may have greater cardiovascular and body composition adaptations compared to persons with paraplegia. twenty subjects will participate in a powered exoskeleton (ekso) for one or twice a week for 12 weeks. the program will involve walking with the robotic suits for 1 hour for persons with complete (n=10) and persons with incomplete (n=10) sci.

Eligibility criteria:
inclusion criteria: 1. a written clearance by the medical doctor . 2. participants will have to be 1 year post-injury with any level of injury. 3. all participants will be between 18-70 years old, men/women, exclusion criteria: 1. participants with body weight greater than 220 lbs 2. whole body t-scores less than -2.5 standard deviation will result in elimination from the program. 3. hip width, upper leg length and lower leg length that do not fit in the robotic suit. 4. previous unhealed fracture in both lower or upper extremities 5. leg length discrepancy that is unlikely to be managed by having shoe inserts 6. high resting blood pressure greater than 130/80 mmhg 7. sudden drop in blood pressure by 20 mmhg especially in persons with tetraplegia. 8. medical conditions prior enrollment similar to cardiovascular disease, uncontrolled type ii diabetes mellitus, uncontrolled hypertension, and those on insulin, pressures sores stage 2 or greater, or urinary tract infection or symptoms. 9. pregnancy
observational vs. ablative treatment for low-grade squamous intraepithelial lesions.

Conditions: LSIL, Low-Grade Squamous Intraepithelial Lesions

Summary: to evaluate the rate of regression and progression of low-grade squamous intraepithelial lesion comparing expectant vs. ablative treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of low-grade squamous intraepithelial lesion by cervical cytology. * positive biopsy for low-grade squamous intraepithelial lesion after colposcopy. exclusion criteria: * serological detection of human immunodeficiency virus (hiv).

Keywords: low-grade squamous intraepithelial lesions
spouse readi (resilience education and deployment information) post deployment telephone support groups

Conditions: Spouses; Military Personnel; Coping Skills

Summary: this 12-month study is for spouses or significant others of service members who have returned from afghanistan or iraq. this study will determine if participating in a telephone discussion group, offering education, skills building, and support, will help increase post-deployment adjustment. there will be 225 spouses recruited for this study.


Eligibility criteria:
inclusion criteria: 1. have a spouse who participated in a deployment to iraq and afghanistan and is at least 1 month post-deployment 2. if not married, must have lived as married for at least one year 3. must be committed to the relationship 4. have a telephone. exclusion criteria: 1. known deployment of spouse in the next six months 2. auditory impairment that would make telephone use difficult.

Keywords: combat disorders spouses support military personnel
neuromuscular training in recreational tennis players

Conditions: Sport Injuries

Summary: the aim of this study is to investigate the effect of upper extremity neuromuscular exercise training on throwing performance, upper extremity strength, and endurance in recreational tennis players. in this context, 24 recreational tennis players will be included in the study. participants will be divided into two equal groups using a simple randomization method. the study group (n=12) will receive progressive upper extremity neuromuscular exercise training twice a week for six weeks before each tennis training session, while the control group will perform only routine warm-up exercises. both groups will be evaluated twice, once at the beginning of the study and again at the end of the six-week intervention. throwing performance will be assessed using the functional throwing performance index (ftpi) and the international tennis number test (itn). upper extremity endurance will be evaluated through the closed kinetic chain upper extremity stability test (ckcuest) and scapula muscle endurance test (sme), while upper extremity strength will be measured using the health ball throw test (hbt) and the y balance upper extremity test (ybuet). statistical analysis will be conducted using spss 24.0 software.


Eligibility criteria:
inclusion criteria: 1. being between the ages of 18-50 2. being a recreational tennis player 3. playing tennis regularly for at least 1 year 4. playing tennis regularly at least twice a week for the last 6 months exclusion criteria: 1. playing another sport along with tennis 2. being a professional tennis player 3. having a history of any injury and/or surgery affecting the upper extremity
comparison of aneuploidy risk evaluations

Conditions: Pregnancy; Down Syndrome; Edwards Syndrome; Patau Syndrome; Turners Syndrome

Summary: this is a prospective, multi-center observational study designed to compare the test results of the verinata health prenatal aneuploidy test to results of conventional prenatal screening for fetal chromosome abnormalities in 'all-risk' pregnancies.


Eligibility criteria:
inclusion criteria: * age 18 years or older at enrollment * clinically confirmed pregnancy * gestational age ≥8 weeks, 0 days * planned or completed prenatal serum screening\* (drawn during 1st and/or 2nd trimester) * pregnancy records accessible and available for data collection (e.g., results from screening, ultrasound examinations, invasive prenatal procedures if performed, and newborn hospital discharge exam) * able to provide consent for participation using language appropriate forms exclusion criteria: * invasive prenatal procedure (amniocentesis or cvs) performed within 2 weeks prior to enrollment * prenatal screening determination by nuchal translucency (nt) measurement only
choline-pet for evaluating the incidence of nodal metastases among newly diagnosed patients of prostate cancer

Conditions: Prostate Cancer

Summary: nodal involvement among patients with prostate cancer is known to be a poor prognostic factor. traditionally, the presence or absence of nodal disease in patients with prostate cancer is ascertained with the use of anatomical imaging methods such as computed tomography (ct) and magnetic resonance imaging (mri). however, the sensitivities of ct and mri for the detection of pelvic nodal disease is rather low, with reports placing the value to lie between 50-80%. positron emission tomography (pet) with the use of carbon-11 or fluorine-18 tagged choline (choline-pet) is an approach which is known to deliver a high sensitivity for the imaging of prostate cancer disease burden in the primary, nodal and the metastatic areas. the investigators in this prospective trial intend to utilize choline-pet among all newly diagnosed patients of prostate cancer who are presumed to be non-n1 (absence of nodal disease on conventional imaging) and non-m1 (absence of metastatic disease on conventional imaging).


Eligibility criteria:
inclusion criteria: * consenting patients * diagnosed prostate cancer exclusion criteria: * metastatic disease at presentation

Keywords: choline pet choline pet-ct positron emission tomography prostate cancer
breast and cervical cancer educational intervention for latinas in western new york

Conditions: Breast Cancer; Cervical Cancer

Summary: this pilot clinical trial studies a breast and cervical cancer educational intervention for latinas in western new york. an outreach program may help minority cancer patients overcome problems that keep them from receiving cancer screening.

primary objectives: i. investigate the extent of linguistic and cultural tailoring necessary to adapt esperanza y vida outreach programs for hispanics in western new york. ii. evaluate the effectiveness of the esperanza y vida program intervention to increase breast and cervical cancer knowledge and screening behaviors in hispanic participants compared to a control health education program on diabetes. iii. determine the factors associated with and/or predictive of screening of hispanics in western new york (wny) as compared to new york city (nyc) and arkansas to describe how the intervention impacts barriers and motivations for screening in diverse hispanic populations. outline: key informant interviews with local "gatekeepers" of hispanic culture groups in wny and focus groups with hispanic cancer survivors with screened and unscreened participants are conducted during the first phase of research. participants are then randomized to 1 of 2 arms. arm i: participants engage in the esperanza y vida educational information session for breast and cervical cancer. arm ii: participants engage in an educational information session for diabetes. after completion of study treatment, participants are followed up at 2 and 8 months.

Eligibility criteria:
inclusion criteria: * men and women who are generally healthy, ambulatory, and able to participate in social events in their communities * no women, men, or children of any ethnic or social background are ever excluded from the educational programs, although recruitment will focus on hispanic/latinos * children may be present with parents, but will not be included in any research activities, unless they are emancipated minors (under 18 and married) * men are included in all of the research activities, but will not be included in the follow-up telephone surveys to assess breast and cervical screening as they do not obtain screening pap smears, clinical breast exams, or mammograms; men may be asked about their intent to assist women in obtaining screening
metoclopramide use in very low birth weight newborns

Conditions: Infant, Premature

Summary: during the first 7 days of life very small babies will receive the drug metoclopramide or a salt solution through an intravenous line. they will also begin to receive a very small amount of breast milk or formula within the first 72 hours of life, in addition toother nourishment that is provided by an intravenous line, according to standard hospital procedure. we think that the babies who receive the medication may reach full oral feeds than babies who receive the salt solution.

clinically stable, premature babies (birth weight between 500 and 1,250g) will be randomized to receive metoclopramide (0.1 mg/kg iv q8h)or an equal volume of placebo for 7 days.a transition feeding schedule will begin within the first 72 hours of life. the time to full feeds for the 2 groups will be analyzed.

Eligibility criteria:
inclusion criteria: * birth weight 500 to 1,250g * clinically stable * no contraindications to initiating minimal enteral feeding exclusion criteria: * birth weight \> 1,250g * clinically unstable * any major congenital anomaly * significant gi pathology * severe iugr * cholestasis

Keywords: metoclopramide feeding very low birthweightnewborn
effect of lllt and ozone to reduce complications after extraction of impacted lower molar

Conditions: Complications of Extraction of Impacted Teeth

Summary: many factors cause third molars to stay impacted in the jaws, hence the extraction of impacted wisdom teeth occurs often in dental clinics. pain, trismus, and edema are typical postoperative complications following third molar surgery. various strategies have been developed to prevent or reduce these postoperative complications, among these is the use of low-level laser therapy (lllt), which demonstrates numerous benefits in lowering pain, trismus, and edema by managing inflammation. the precise biological mechanism of action remains unknown. there seems to be evidence that it may have neuro-pharmacological impacts on the production, metabolism, and release of a number of biological compounds, the other option is use of ozone which has antimicrobial effectiveness (viricidal, bactericidal, and fungicidal). additional well-known advantages include immunological modulatory and stimulating actions, including anti-inflammatory, biosynthetic, anti-hypoxic, and bioenergetic characteristics. ozone can interact with blood components in the right amounts to positively impact oxygen metabolism and cell energy while also triggering antioxidant defense mechanisms


Eligibility criteria:
inclusion criteria: * patients who had mandibular third molar, totally or partially impacted in the bone (class ii-iii and position b, pell and gregory's classification), in need of surgical extraction, which were evaluated clinically and by radiological examination. * patients who were in age range between 18-40 years old. * patients who were willing to compliance with study and were available for follow up. * patients should be with good oral hygiene and without any acute illness exclusion criteria: * patients with medical condition that prevent any surgical intervention such as patient with recent myocardial infarction, bleeding disorders, psychiatric problem and patients with pacemaker, uncontrolled systemic disease, immunocompromised patient and patients taking corticosteroid and anti-inflammatory drugs. * patients with history of head and neck radiotherapy. * pregnant or lactation women * active advanced uncontrolled periodontal disease and bad oral hygiene, or patients with local acute infection in relation to third molar especially pericoronitis. * patients who suffer from photodermatoses and photosensitized patients (photoallergies). * hyperthyroidism
allergy skin patch artificial intelligence (ai)

Conditions: Allergic Contact Dermatitis

Summary: the purpose of this research is to assess human and artificial intelligence performance in grading contact dermatitis reactions in healthy volunteers.

study participation involves three visits to the study site on days 1, 3, and 5, and completion of a demographics and allergy history questionnaire. researchers will review medical history and current medications. on day 1 a patch will be applied with 10 allergens and a routine skin examination will be conducted and a photograph will be taken of the forearm. on day 3, subjects will return to remove the patch test and have photographs of the area taken. on day 5, the final assessment for allergic contact dermatitis will be performed and photographs of the area taken. key information: the most common side effect of skin testing is slightly swollen, red, itchy bumps (wheals). these wheals may be most noticeable during the test. in some, an area of swelling, redness and itching may develop a few hours after the test and remain for a couple of days. rarely, allergy skin tests can produce a severe, immediate allergic reaction. the patches are worn on the forearm for 48 hours. during this time, bathing and activities that cause heavy sweating should be avoided. irritated skin at the patch site may indicate an allergy. if a positive test result is documented, a medical professional will provide education and recommend follow up with primary care provider.

Eligibility criteria:
inclusion criteria * adults over the age of 18 * willing and able to provide informed consent exclusion criteria * under 18 years of age * has used topical or oral steroids two weeks prior to patch testing * currently taking immunosuppression agents or is immunocompromised due to medical condition * no sunburn or rash at site of testing * women who are breastfeeding or pregnant. * treatment with ultraviolet (uv) light (including tanning) during the two weeks prior to visit. * subjects unable to comply with patch test study requirements including multiple return visits and activity restrictions (e.g., protecting patch test area from excess moisture due to showering)
a study of the safety and efficacy of chronically administered mdl 28,574a in the treatment of hiv-infected patients

Conditions: HIV Infections

Summary: to characterize the safety and efficacy of fixed doses of mdl 28,574a administered alone and in combination with zidovudine ( azt ) in patients with asymptomatic or mildly symptomatic hiv infection. to examine the demographic effects on population pharmacokinetics and pharmacodynamics of mdl 28,574a alone and in combination with azt.


Eligibility criteria:
inclusion criteria patients must have: * hiv infection. * asymptomatic or mildly symptomatic. * cd4 count 100 - 300 cells/mm3. prior medication: allowed: * prior antiretroviral agents for up to 6 months per agent. exclusion criteria co-existing condition: patients with the following condition are excluded: unable or unwilling to comply with study procedures. concurrent medication: excluded: * chemoprophylactic therapy for mycobacterial infection. * any nonstudy prescription medications without approval of investigator. patients with the following prior conditions are excluded: * history of grade 3 or 4 toxicity to \<= 600 mg/day azt. * history of intolerance to lactose. * chronic diarrhea within 6 months prior to study entry. * unexplained intermittent or chronic fever, defined as temperature \>= 38.5 c for any 7 days within the 30 days prior to study entry. prior medication: excluded: * antiretroviral therapy within 2 weeks prior to study entry. * prior hiv vaccines. * biological response modifiers within 30 days prior to study entry. * prior foscarnet. * any investigational drug with a washout \< 5 half-lives prior to study entry. * any medications known to alter renal, hepatic, or hematologic / immunologic function (such as barbiturates, phenothiazines, cimetidine, immunomodulators, etc.) within 14 days prior to study entry. recent history of alcohol and/or drug abuse.

Keywords: drug therapy, combination acquired immunodeficiency syndrome aids-related complex zidovudine mdl 28574